Journal
PEDIATRIC BLOOD & CANCER
Volume 62, Issue 7, Pages 1171-1175Publisher
WILEY
DOI: 10.1002/pbc.25454
Keywords
epratuzumab; monoclonal antibody; relapsed ALL
Categories
Funding
- Children's Oncology Group [U10 CA98543, U10 CA98413, U10 CA180899]
Ask authors/readers for more resources
BackgroundGiven the success of immunotherapeutic approaches in hematologic malignancies, the COG designed a phase I/II study to determine whether the addition of epratuzumab (anti-CD22) to an established chemotherapy platform improves rates of second remission (CR2) in pediatric patients with B-lymphoblastic leukemia (B-ALL) and early bone marrow relapse. ProcedureTherapy consisted of three established blocks of re-induction chemotherapy. Epratuzumab (360mg/m(2)/dose) was combined with chemotherapy on weeklyx4 (B1) and twice weeklyx4 [eight doses] (B2) schedules during the first re-induction block. Remission rates and minimal residual disease (MRD) status were compared to historical rates observed with the identical chemotherapy platform alone. ResultsCR2 was achieved in 65 and 66%, of the evaluable B1 (n=54) and B2 patients (n=60), respectively; unchanged from that observed historically without epratuzumab. Rates of MRD negativity (<0.01%) were 31% in B1 (P=0.4128) and 39% in B2 patients (P=0.1731), compared to 25% in historical controls. The addition of epratuzumab was well tolerated, with a similar toxicity profile to that observed with the re-induction chemotherapy platform regimen alone. ConclusionsEpratuzumab was well tolerated in combination with re-induction chemotherapy. While CR2 rates were not improved compared to historical controls treated with chemotherapy alone, there was a non-significant trend towards improvement in MRD response with the addition of epratuzumab (twice weekly for eight doses) to re-induction chemotherapy. Pediatr Blood Cancer 2015;62:1171-1175. (c) 2015 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available